Status | Study |
RECRUITING |
Study Name: Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis Condition: Primary Myelofibrosis Date: 2021-04-09 Interventions: Experimental |
Recruiting |
Study Name: Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis Condition: Myelofibrosis Date: 2016-09-30 Interventions: Other: Hematopoietic Stem Cell Transplant This observational study will compare outcomes of prospectivel |
Recruiting |
Study Name: Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis Condition: Primary Myelofibrosis Secondary Myelofibr Date: 2016-09-26 Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation |
Recruiting |
Study Name: Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis Condition: Myelofibrosis Date: 2016-08-26 |
Recruiting |
Study Name: Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis Condition: Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase Date: 2016-08-09 Interventions: Biological: Durvalumab Given I |
Active, not recruiting |
Study Name: Study of Ruxolitinib for Patients With Myelofibrosis (MF) Condition: Myelofibrosis Date: 2016-05-20 Interventions: Drug: Ruxolitinib Participants |
Recruiting |
Study Name: Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg Condition: Myelofibrosis Date: 2016-03-08 Interventions: Drug: Ruxolotinib Ruxolitinib |
Withdrawn |
Study Name: A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis Condition: Primary Myelofibrosis Date: 2015-10-21 Interventions: Biological: Pacritinib QD (Once a day) |
Suspended |
Study Name: Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor Condition: Primary Myelofibrosis Date: 2015-04-21 Interventions: Drug: Imetelstat 9.4 milligram/kilogram (mg/kg) |
Recruiting |
Study Name: P1101 in Treating Patients With Myelofibrosis Condition: Primary Myelofibrosis Secondary Myelofibr Date: 2015-02-17 Interventions: Other: Laboratory Biomarker Analysis |